TrialHuman vaccines & immunotherapeutics2022

A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months.

Hitt Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.